Merz Therapeutics’ Post

Takeda GmbH Segment Revenues Takeda GmbH’s segment revenues (in Germany) for 2022 and 2023 showcase a diverse portfolio with varying performance across different therapeutic areas. The Gastroenterology segment remained the largest contributor, generating €x million in 2022 and €x million in 2023, representing a modest growth of 0.8%. The Rare Diseases segment, however, experienced a decline of 8.1%, with revenues dropping from €x million to €x million. The Plasma-based Therapies segment saw a significant decrease of 27.4%, from €x million to €x million. On the other hand, the Oncology segment grew by 6.6%, from €x million to €x million, and the Neurology segment exhibited a notable 28.0% increase, rising from €x million to €x million. The Vaccine segment witnessed a substantial growth of 102.9%, with revenues doubling from €x million to €x million. Finally, the Other segment, encompassing various therapeutic areas, experienced a decline of 11.6%, from €x million to €x million. https://lnkd.in/emG6XH6A

Takeda GmbH Segment Revenues Takeda GmbH’s segment revenues (in Germany) for 2022 and 2023 showcase a diverse portfolio with varying performance across different therapeutic areas. The Gastroenterology segment remained the largest contributor, generating €x million in 2022 and €x million in 2023, representing a modest growth of 0.8%. The Rare Diseases segment, however, experienced a decline of 8.1%, with revenues dropping from €x million to €x million. The Plasma-based Therapies segment saw a significant decrease of 27.4%, from €x million to €x million. On the other hand, the Oncology segment grew by 6.6%, from €x million to €x million, and the Neurology segment exhibited a notable 28.0% increase, rising from €x million to €x million. The Vaccine segment witnessed a substantial growth of 102.9%, with revenues doubling from €x million to €x million. Finally, the Other segment, encompassing various therapeutic areas, experienced a decline of 11.6%, from €x million to €x million. https://lnkd.in/eXuAbJa9

Lewy Body Dementia Pipeline Assessment 2024: Therapies, Clinical Trials, Key Companies involved by DelveInsight | Jazz Pharma, Allergan, Noven Pharma, Takeda Pharma, Eli Lilly, Mallinckrodt Pharma: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Lewy Body Dementia pipeline constitutes key companies continuously working towards developing Lewy Body Dementia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Henry: Since the FDA decided not to approve MDMA-assisted therapy in August, you've stepped down from the board of Lykos Therapeutics, MAPS' for-profit subsidiary. What do you think is the right next step for the company? Rick: First off, Lykos isn't really a subsidiary anymore. Multidisciplinary Association for Psychedelic Studies (MAPS) only owns about 42% now. While we've got 10-to-1 voting shares and we appoint most of the board, we admittedly made a choice that hasn’t worked out well. We basically handed off all responsibility for managing Lykos to its own board, which has acted more independently than necessary. I think the key failure Lykos made was thinking we'd evolved to a point where the controversy over psychedelics was essentially over—that this was now just a rational process. They thought all they had to do was present compelling data to the FDA, and the data would speak for itself. So Lykos adopted a "quiet period," which is something traditional pharma does while the FDA's reviewing a drug. But that strategy is disastrous when you're dealing with a substance that's already out in the culture. During this quiet period, Lykos not only didn't respond to misinformation and critiques; they blocked me and MAPS from responding, too. We couldn't answer reasonable questions that had good answers. Culture really did matter in the end. Our critics weren't staying quiet, and this isn't some unknown drug. 22 million Americans have already used ecstasy or MDMA. You can't just ignore that context. So what Lykos needs to do now is speak up. Tell the story of how the therapy was developed. Get out there and explain the study design process, address the critiques, and engage with the culture. They need to recognize that this isn't just about convincing the FDA; it's about convincing the public, the media, and even the FDA advisory committee members who seem to be more influenced by what they read in the Washington Post than in their briefing packages. Most importantly, Lykos needs to ditch this idea of being a traditional pharma company and embrace being a drug-plus-therapy company. That's what makes MDMA-assisted therapy unique and effective, and that’s what will save the most lives.

Calliditas Therapeutics 𝗔𝗕'𝘀 𝗔𝗺𝗲𝗿𝗶𝗰𝗮𝗻 𝗱𝗲𝗽𝗼𝘀𝗶𝘁𝗮𝗿𝘆 𝗿𝗲𝗰𝗲𝗶𝗽𝘁𝘀 𝘀𝘂𝗿𝗴𝗲𝗱 𝗼𝘃𝗲𝗿 𝟳𝟬% 𝗶𝗻 𝗽𝗿𝗲𝗺𝗮𝗿𝗸𝗲𝘁 𝘁𝗿𝗮𝗱𝗶𝗻𝗴 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗮 $𝟭.𝟭 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝘁𝗮𝗸𝗲𝗼𝘃𝗲𝗿 𝗯𝗶𝗱 𝗯𝘆 𝗝𝗮𝗽𝗮𝗻𝗲𝘀𝗲 𝗰𝗼𝗻𝗴𝗹𝗼𝗺𝗲𝗿𝗮𝘁𝗲 Asahi Kasei. The offer, at𝟮𝟬𝟴 𝗦𝘄𝗲𝗱𝗶𝘀𝗵 𝗸𝗿𝗼𝗻𝗼𝗿 𝗽𝗲𝗿 𝘀𝗵𝗮𝗿𝗲, represents an 83% premium to Calliditas's previous closing price. The Stockholm-based company, which markets the kidney disease drug #Tarpeyo, received a unanimous recommendation from its board to accept the offer. This acquisition underscores both companies' commitment to advancing treatments for immunoglobulin A nephropathy (IgAN) and aligns with Asahi Kasei's strategy to expand globally in the healthcare sector, particularly in immunology and transplantation. https://lnkd.in/eHmQPuGm #PharmaNews #HealthcareInnovation #StockMarket #Biotech #Acquisition

The pharmaceutical landscape is undergoing a transformative shift, driven by advancements in critical areas such as oncology, biosimilars, biologics, and specialty medications for rare and orphan diseases. Asembia's #AXS24 Summit presents a valuable opportunity to engage in discussions around these developments, particularly promising therapies targeting MASH, Alzheimer's, and advancements in oncology drugs and GLP-1s. These advancements reinforce CoverMyMeds' dedication to developing innovative solutions that support our mission to help people get the medicine they need to live healthier lives. What are you looking forward to at #Asembia24? Share your thoughts in the comments below. https://lnkd.in/eMtSuePa

I have been an advocate for holistic, natural approaches for over 20 years. Finally last year for the first time had a breakthrough in healing from myself an my clients using ketamine-assisted psychotherapy however thew goal is to be able to provide MDMA/Psilocybin Assisted-Psychotherapy. Read below: During this quiet period, Lykos not only didn't respond to misinformation and critiques; they blocked me and MAPS from responding, too. We couldn't answer reasonable questions that had good answers. Culture really did matter in the end. Our critics weren't staying quiet, and this isn't some unknown drug. 22 million Americans have already used ecstasy or MDMA. You can't just ignore that context. So what Lykos needs to do now is speak up. Tell the story of how the therapy was developed. Get out there and explain the study design process, address the critiques, and engage with the culture. They need to recognize that this isn't just about convincing the FDA; it's about convincing the public, the media, and even the FDA advisory committee members who seem to be more influenced by what they read in the Washington Post than in their briefing packages. Most importantly, Lykos needs to ditch this idea of being a traditional pharma company and embrace being a drug-plus-therapy company. That's what makes MDMA-assisted therapy unique and effective, and that’s what will save the most lives. #MDMA #psilocybin #PTSD #medicationresistantdepression #integrativemedicine

Market buzz! Karuna Therapeutics leaps 47% after Bristol Myers Squibb's $14 billion deal announcement. 📈🤝 Following the Announcement of a $14 Billion Deal by Bristol Myers Squibb, Karuna Therapeutics Jumps 47% Read More: https://bit.ly/3RUesL4 #BristolMyersSquibb #KarunaTherapeutics #MarketNews #BusinessDeals #StockMarketUpdate #HealthcareSector #FinancialMarket #WellnessUpdates

📉 APRINOIA Therapeutics Lowers IPO Deal Size I just saw that APRINOIA Therapeutics, a biotech in Phase 3 trials focusing on neurodegenerative diseases, has reduced the size of its IPO. The company now plans to raise $6 million by offering 0.5 million shares, adjusting the price range down to $10-$12 from the initial $10-$14. This change means they’ll raise about 8% less than initially planned, reaching a market value of $331 million at the midpoint. APRINOIA is developing diagnostic tools and therapies for diseases like Alzheimer's and Progressive Supranuclear Palsy (PSP). Their most advanced candidate, APN-1607, is undergoing a Phase 3 trial in China for Alzheimer's, with hopes of filing for approval in China soon. They also received FDA clearance to test APN-1607 for PSP in the U.S. However, there's some uncertainty around the effectiveness of using tau buildup as a marker for these diseases, which may be contributing to the lower demand. It will be interesting to see if their results are compelling enough to move forward with U.S. trials. APRINOIA is set to list on the Nasdaq under the ticker APRI. Let's see how this one plays out! #APRINOIA #Biotech #IPO #Microcap #Alzheimers #PSP #StockMarket #Nasdaq #Investing #FDA #Pharma https://lnkd.in/dnVibZuT

Bristol Myers Squibb's recent announcement to acquire Karuna Therapeutics for $14 billion in cash, a deal that values Karuna at $330 per share, has made waves in the biopharmaceutical world. Karuna's stock surged more than 47% in response to the news, highlighting the significance of this move. This strategic acquisition will play a pivotal role in expanding Bristol Myers' drug pipeline, particularly after facing challenges with declining demand for their blood cancer drug, Revlimid. Karuna's focus on developing medications for neurological and psychiatric conditions, including the promising antipsychotic KarXT, aligns with Bristol Myers' vision for growth in the neuroscience sector. KarXT, set to be a potential treatment for adults with schizophrenia starting in late 2024, is also under evaluation for addressing Alzheimer's disease psychosis and bipolar disorder. This acquisition reflects the industry's ongoing commitment to advancing treatments in these critical areas. While the deal is still pending closure in the first half of 2024, it marks a significant step forward for both companies, with the potential to bring innovative treatments to patients living with these challenging conditions. #KarunaTherapeutics #BristolMyersSquibb #Biopharmaceutical #FutureOfHealthcare #Healthcare Source: https://lnkd.in/g-J36BBn